<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333162</url>
  </required_header>
  <id_info>
    <org_study_id>IRB14-0709</org_study_id>
    <secondary_id>NCI-2014-02469</secondary_id>
    <secondary_id>IRB14-0709</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <nct_id>NCT02333162</nct_id>
  </id_info>
  <brief_title>Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant</brief_title>
  <official_title>A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and the best dose of intensity modulated total
      marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in
      treating patients with cancers of the blood (hematologic) that have returned after a period
      of improvement (relapsed) undergoing a second donor stem cell transplant. IMTMI is a type of
      radiation therapy to the bone marrow that may be less toxic and may also reduce the chances
      of cancer to return. Giving fludarabine phosphate, melphalan, and IMTMI before a donor stem
      cell transplant may help stop the growth of cells in the bone marrow, including normal
      blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune
      system from rejecting the donor's stem cells. When the healthy stem cells from a donor are
      infused into the patient they may help the patient's bone marrow make stem cells, red blood
      cells, white blood cells, and platelets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. The determine the maximum tolerated dose (MTD) of intensity-modulate total marrow
      irradiation (IMTMI) in combination with fludarabine (fludarabine phosphate)/melphalan as
      conditioning for second allogeneic stem cell transplantation for patients with hematologic
      malignancies.

      SECONDARY OBJECTIVES:

      I. To determine the overall toxicity and day 100 transplant related mortality after second
      allogeneic hematopoietic stem cell transplantation conditioned with increasing doses of
      intensity-modulate total marrow irradiation (IMTMI) in combination with
      fludarabine/melphalan.

      II. To determine the time to neutrophil and platelet engraftment after second allogeneic
      hematopoietic stem cell transplantation conditioned with increasing doses of
      intensity-modulate total marrow irradiation (IMTMI) in combination with
      fludarabine/melphalan.

      III. To determine the overall survival (OS) and event-free-survival (EFS) in patients with
      hematologic undergoing second allogeneic hematopoietic stem cell transplant (HSCT) after
      conditioning with fludarabine/melphalan and IMTMI.

      OUTLINE: This is a dose-escalation study of IMTMI.

      CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) over 30
      minutes daily on days -7 to -3 and melphalan IV on day -2. Patients also undergo IMTMI twice
      daily (BID) for 2 to 5 days between days -7 to -3.

      TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant (PBSCT) or bone
      marrow transplant (BMT) on day 0.

      GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive tacrolimus IV continuously
      over 24 hours or orally (PO) BID on days -2 to 180 with taper thereafter and mycophenolate
      mofetil IV every 8 hours or PO on days 0-28 (for matched donors) or days 0-40 (for
      alternative donors) with taper to day 60.

      After completion of treatment, patients are followed up periodically for 1 year and then
      yearly for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of conditioning regimen defined as any grade III or higher dose-limiting toxicity, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Up to 30 days post second allo-SCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of adverse events, graded according to the NCI CTCAE version 4.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>First day in which the ANC is &gt; 500/mm^3 for 3 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>First day the platelet count is &gt; 20,000/mm^3 without transfusion support for 7 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free-survival (EFS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes daily on days -7 to -3 and melphalan IV on day -2. Patients also undergo IMTMI BID for 2 to 5 days between days -7 to -3.
TRANSPLANT: Patients undergo allogeneic PBSCT or BMT on day 0.
GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO BID on days -2 to 180 with taper thereafter and mycophenolate mofetil IV every 8 hours or PO on days 0-28 (for matched donors) or days 0-40 (for alternative donors) with taper to day 60.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMTMI</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Marrow Irradiation</intervention_name>
    <description>Undergo IMTMI</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic BMT</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
    <other_name>Advagraf</other_name>
    <other_name>FK 506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the following diseases: acute myeloid leukemia (AML) and high risk
             myelodysplastic syndrome (MDS) undergoing second allogeneic (allo)-stem cell
             transplant (SCT) using the same donor or different donor for disease relapse; patients
             with other hematologic malignancies, including acute lymphoblastic leukemia (ALL),
             will be at the discretion of the investigators

          -  Karnofsky performance status of 70 or above

          -  Life expectancy is not severely limited by concomitant illness

          -  Adequate cardiac and pulmonary function; patients with decreased left ventricular
             ejection fraction (LVEF) =&lt; 40% or diffusion capacity of carbon monoxide (DLCO) =&lt; 50%
             of predicted will be evaluated by cardiology or pulmonary prior to enrollment on this
             protocol

          -  Serum creatinine =&lt;1.5 mg/dL or creatinine clearance &gt; 50 ml/min; some patients with
             minor deviations may be accepted on protocol after discussion with the principal
             investigator (PI)

          -  Serum bilirubin =&lt; 2.0 mg/dl; some patients with minor deviations may be accepted on
             protocol after discussion with the PI

          -  Serum glutamic oxaloacetic transaminase (SGPT) &lt; 5 x upper limit of normal; some
             patients with minor deviations may be accepted on protocol after discussion with the
             PI

          -  No evidence of chronic active hepatitis or cirrhosis

          -  Human immunodeficiency virus (HIV)-negative

          -  Patient is not pregnant

          -  Patient or guardian able to sign informed consent

          -  DONOR: Since these patients already had first allo-SCT; in the majority time, the same
             matched donor has been used for second allo-SCT; if the patients have multiple donors,
             alternative matched (8/8 or 10/10) donor could be used for the second allo-SCT; the
             donor could be matched related donors or matched unrelated donors from registry

          -  DONOR: If more than one potential volunteer unrelated donor is considered suitable,
             further selection of the most suitable donor will be prioritized as follows or will
             follow our institutional guideline from our stem cell transplant standard operating
             procedure (SOP):

               -  Age of donor (18-24 &gt; 25-34 &gt; 35-44 &gt; 45+)

               -  Sex of donor (male &gt; female, nulliparous female &gt; parous, multiparous female)

               -  Cytomegalovirus (CMV) status, if recipient is CMV seronegative (CMV- &gt; CMV+
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongtao Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongtao Liu</last_name>
      <phone>773-834-0589</phone>
      <email>hliu2@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Hongtao Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

